Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al.
Rudnicka
Lidia
L
Olszewska
Malgorzata
M
Kardynal
Agnieszka
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab